Ardelyx Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ardelyx stock.
View analyst ratings for Ardelyx or view top-rated stocks.

Wall Street analysts have given Ardelyx a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ardelyx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Ardelyx is scheduled to release its next quarterly earnings announcement on Friday, March 5th 2021.
View our earnings forecast for Ardelyx.

Ardelyx, Inc. (NASDAQ:ARDX) announced its quarterly earnings results on Tuesday, November, 10th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating the Zacks' consensus estimate of ($0.28) by $0.08. The biopharmaceutical company had revenue of $2.71 million for the quarter, compared to the consensus estimate of $1.31 million. Ardelyx had a negative trailing twelve-month return on equity of 53.93% and a negative net margin of 1,063.74%.
View Ardelyx's earnings history.

Ardelyx's stock was trading at $5.98 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ARDX shares have increased by 8.2% and is now trading at $6.47.
View which stocks have been most impacted by COVID-19.

3 analysts have issued twelve-month price objectives for Ardelyx's shares. Their forecasts range from $14.00 to $14.00. On average, they expect Ardelyx's share price to reach $14.00 in the next year. This suggests a possible upside of 116.4% from the stock's current price.
View analysts' price targets for Ardelyx or view top-rated stocks among Wall Street analysts.

Some companies that are related to Ardelyx include Arcus Biosciences (RCUS), Endo International (ENDP), Dicerna Pharmaceuticals (DRNA), Prestige Consumer Healthcare (PBH), Harmony Biosciences (HRMY), Applied Molecular Transport (AMTI), Myovant Sciences (MYOV), ADC Therapeutics (ADCT), Stoke Therapeutics (STOK), Generation Bio (GBIO), Madrigal Pharmaceuticals (MDGL), Aurinia Pharmaceuticals (AUPH), NGM Biopharmaceuticals (NGM), Pandion Therapeutics (PAND) and Praxis Precision Medicines (PRAX).
View all of ARDX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD).

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Ardelyx's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.56%), Price T Rowe Associates Inc. MD (2.77%), Dimensional Fund Advisors LP (2.06%), Pekin Hardy Strauss Inc. (1.75%), Candriam Luxembourg S.C.A. (1.52%) and Ikarian Capital LLC (1.28%). Company insiders that own Ardelyx stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Justin A Renz, Mark Kaufmann, Michael Raab, Robert Blanks, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends for Ardelyx.

ARDX stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Renaissance Technologies LLC, Pekin Hardy Strauss Inc., Wells Fargo & Company MN, Price T Rowe Associates Inc. MD, State of Wisconsin Investment Board, Principal Financial Group Inc., and Northern Trust Corp. Company insiders that have sold Ardelyx company stock in the last year include Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Justin A Renz, Michael Raab, Robert Blanks, Scott D Sandell, and Susan Rodriguez.
View insider buying and selling activity for Ardelyx or view top insider-selling stocks.

ARDX stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Janus Henderson Group PLC, Silverarc Capital Management LLC, Russell Investments Group Ltd., BlackRock Inc., Bailard Inc., ExodusPoint Capital Management LP, and Nuveen Asset Management LLC.
View insider buying and selling activity for Ardelyx or or view top insider-buying stocks.

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARDX stock can currently be purchased for approximately $6.47.

Ardelyx has a market capitalization of $583.90 million and generates $5.28 million in revenue each year. The biopharmaceutical company earns $-94,940,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis.

Ardelyx employs 88 workers across the globe.

The official website for Ardelyx is www.ardelyx.com.

Ardelyx is headquartered at 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555.

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]